Automated scoring to assess RAD51-mediated homologous recombination in ovarian patient-derived tumor organoids.

PARP inhibitors (PARPi) have been shown to improve progression-free survival, particularly in homologous recombination deficient (HRD) ovarian cancers. Identifying patients eligible to PARPi is currently based on next-generation sequencing (NGS), but the persistence of genomic scars in tumors after restoration of HR or epigenetic changes can be a limitation. Functional assays could thus be used to improve this profiling and faithfully identify HRD tumors.

Benthic macroinvertebrate diversity and function in an agricultural constructed wetland affected by agrochemical pressure (Seine-et-Marne, France).

Constructed wetlands (CWs), originally designed to mitigate chemical water pollution, often host noticeable aquatic fauna. However, little is known about the impact of the contaminants circulating within CWs on this local fauna, questioning the role of CWs as ecological refuges or traps. We aimed to assess the potential of an agricultural CWs in northern France to act as an ecological trap for aquatic fauna and the potential consequences on wetland functioning.

Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs.

Metastatic cancer remains incurable as patients eventually loose sensitivity to targeted therapies and chemotherapies, further leading to poor clinical outcome. Thus, there is a clear medical gap and urgent need to develop efficient and improved targeted therapies for cancer patients. In this study, we investigated the role of DYRK1A kinase in regulating cancer progression and evaluated the therapeutic potential of DYRK1A inhibition in invasive solid tumors, including colon and triple-negative breast cancers.